Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELPIS trial
2019-005019-18Phase 2Terminated
- Sponsor
- Fundació Clínic per a la Recerca Biomèdica
- Start
- Sep 2025
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of trastuzumab, pertuzumab, paclitaxel, trastuzumab emtansine, cyclophosphamide and 2 more in breast cancer (2 arms), sponsored by Fundació Clínic per a la Recerca Biomèdica. Started Sep 2025; status: terminated.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2019-005019-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-005019-18.